Open an Account
search icon
4
NOTIFICATIONS
Best Algo trading app in India
Bigul

Suven Pharmaceuticals Ltd - 543064 - Closure of Trading Window

 We wish to inform you that the "Trading Window" for dealing in the securities of the Company will be closed for the Designated Persons, their immediate relatives covered under the said Code of the Company from 1st April, 2022 and the same will remain closed till 48 hours after the declaration of Financial Results for the quarter and year ending 31st March, 2022, to the public, in terms of the Code of Conduct of the Company under the SEBI (Prohibition of Insider Trading) Regulations, 2015. This is for your information and record.
31-03-2022
Bigul

Suven Pharmaceuticals Ltd - 543064 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate

 Pursuant to Regulation 39(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that the Company has received intimation from shareholder of the Company, regarding loss of share certificate(s) as details mentioned below. A copy of request letter received from Shareholder is enclosed herewith. Name of the Holder Folio No. No. of Shares Certificate No.(s) Distinctive Nos. date of receipt of information From To SEETA RAMAIAH NANDAM SPC0164142 2000 164142 127066708 127068707 25/03/2022 2000 276998 254359105 254361104 The above said shareholder(s) of these shares have requested the company to issue of duplicate share certificate(s) in lieu of the original share certificate(s).
28-03-2022
Bigul

Suven Pharmaceuticals Ltd - 543064 - Clarification sought from Suven Pharmaceuticals Ltd

 The Exchange has sought clarification from Suven Pharmaceuticals Ltd on March 24, 2022, with reference to Movement in Volume.The reply is awaited.
24-03-2022

Suven Pharma: Steady cash flow conversion opportunity merits attention

 Suven Pharma remains conservative in its outlook and provides visibility for the next six months. It is confident of executing Q3 sales run rate for the next two quarters
10-02-2022

Earnings Call for Q3FY22 of Suven Pharmaceuticals

 Conference Call with Suven Pharmaceuticals Management and Analysts on Q3FY22 Performance and Outlook. Listen to the full earnings transcript.
09-02-2022
Bigul

Suven Pharmaceuticals Ltd - 543064 - Announcement under Regulation 30 (LODR)-Newspaper Publication

 Pursuant to Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, please find enclosed the copies of the newspaper advertisements regarding to Financial Results of the Company for the quarter and nine months ended December 31, 2021. The advertisements as appeared today i.e. February 9, 2022 in Andhra Prabha (Telugu) and Business Standard. The above information will also be hosted on the website of the Company at: https://www.suvenpharm.com/index.php/investors/corporate-info/advertisements This is for your information and record.
09-02-2022

Suven Pharma Consolidated December 2021 Net Sales at Rs 391.59 crore, up 42.43% Y-o-Y

 NULL
09-02-2022
Bigul

Suven Pharmaceuticals Ltd - 543064 - Announcement under Regulation 30 (LODR)-Investor Presentation

 Please find attached Investor Presentation
08-02-2022
Bigul

Suven Pharmaceuticals Ltd - 543064 - Board declares Interim Dividend & One-time Special Dividend

 Suven Pharmaceuticals Ltd has informed BSE that the Board of Directors of the Company at its meeting held on February 08, 2022, inter alia, has declared an interim Dividend of Rs.1.00 per equity share (100% of Face value of Rs.1.00 each) and one-time special dividend of Rs. 2.00 per equity share (200% of Face value of Rs.1.00), totaling to Rs. 3.00 per equity share (300% of Face value of Rs. 3.00 each) for the financial year 2021-22.The above said dividend will be paid on and from February 22, 2022.
08-02-2022
Bigul

Q3FY22 Quarterly Result Announced for Suven Pharmaceuticals Ltd.

 Suven Pharmaceuticals declares Q3FY22 result: The Company is focused on the business of Contract Development and Manufacturing Operations (CDMO). The Suven Pharma Inc., the WOS of our Company has divested its entire stake (25% amounting to $35.00 Mn) in M/s Rising Pharma Holdings, Inc., USA on 13th Dec,2021 to Raisin Acquisition Co, Inc., one of the investment arms of H.I.G. Capital, a leading global alternative investment firm in USA through structured deal. As part of the structured deal our WOS, Suven Pharma, Inc., received in the form of cash component of $ 41.555 Mn and a stake valued at $15.803 Mn in Raisin Aggregators L.P. Accordingly, Rising Pharma Holdings, Inc., USA has ceased to be an associate company w.e.f 13th Dec'2021. Hence, the share of profits of associate has not been considered in the consolidated financial statements for the Quarter ended 31st Dec'2021. The Board has declared an interim Dividend of Rs.1.00 per equity share (100% of Face value of Rs.1.00 each) and one-time special dividend of Rs. 2.00 per equity share (200% of Face value of Rs.1.00), totaling to Rs. 3.00 per equity share (300% of Face value of Rs. 3.00 each) for the financial year 2021-22. The Board in its meeting held on 8th February 2022, has given its in-principle approval to evaluate the acquisition opportunity of Caper Pharma Pvt. Ltd., an SEZ unit in Hyderabad engaged in Formulations. The Company will evaluate the proposal subject to financial, tax and legal due diligence to finalize the definitive agreements. The COVID-19 continuous to impact the business and research operations in India and our wholly owned subsidiary, Suven pharma, Inc., USA. Result PDF
08-02-2022
Next Page
Close

Let's Open Free Demat Account